ID: ALA556420

Max Phase: Preclinical

Molecular Formula: C32H26F3N3O2

Molecular Weight: 541.57

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)CCN1CCc2c(c3ccc(F)cc3n2Cc2cccc(/C=C/c3ccc4cc(F)c(F)cc4n3)c2)C1

Standard InChI:  InChI=1S/C32H26F3N3O2/c33-23-6-9-25-26-19-37(13-11-32(39)40)12-10-30(26)38(31(25)16-23)18-21-3-1-2-20(14-21)4-7-24-8-5-22-15-27(34)28(35)17-29(22)36-24/h1-9,14-17H,10-13,18-19H2,(H,39,40)/b7-4+

Standard InChI Key:  GDMSHJVAGDQAPT-QPJJXVBHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 541.57

Molecular Weight (Monoisotopic): 541.1977

AlogP: 6.66

#Rotatable Bonds: 7

Polar Surface Area: 58.36

Molecular Species: ACID

HBA: 4

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.51

CX Basic pKa: 7.41

CX LogP: 3.91

CX LogD: 3.68

Aromatic Rings: 5

Heavy Atoms: 40

QED Weighted: 0.25

Np Likeness Score: -1.01

References

1. Bonjoch J, Diaba F, Pagès L, Pérez D, Soca L, Miralpeix M, Vilella D, Anton P, Puig C..  (2009)  Synthesis and structure-activity relationships of gamma-carboline derivatives as potent and selective cysLT(1) antagonists.,  19  (15): [PMID:19505824] [10.1016/j.bmcl.2009.05.094]

Source

Source(1):

• Scientific Literature